Immunome, Inc.
IMNM
$20.86
$0.150.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | 4.02M | 2.93M | 2.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | 4.02M | 2.93M | 2.74M |
| Cost of Revenue | 50.77M | 49.19M | 40.45M | 36.87M | 47.89M |
| Gross Profit | -50.77M | -49.19M | -36.44M | -33.95M | -45.15M |
| SG&A Expenses | 12.09M | 10.95M | 10.04M | 10.69M | 10.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.86M | 60.14M | 50.49M | 47.56M | 58.34M |
| Operating Income | -62.86M | -60.14M | -46.48M | -44.64M | -55.60M |
| Income Before Tax | -69.90M | -57.46M | -43.40M | -41.64M | -80.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.90M | -57.46M | -43.40M | -41.64M | -80.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.90M | -57.46M | -43.40M | -41.64M | -80.25M |
| EBIT | -62.86M | -60.14M | -46.48M | -44.64M | -55.60M |
| EBITDA | -62.23M | -59.55M | -45.84M | -44.03M | -55.15M |
| EPS Basic | -0.74 | -0.65 | -0.50 | -0.52 | -1.28 |
| Normalized Basic EPS | -0.39 | -0.41 | -0.31 | -0.33 | -0.53 |
| EPS Diluted | -0.74 | -0.65 | -0.50 | -0.52 | -1.28 |
| Normalized Diluted EPS | -0.39 | -0.41 | -0.31 | -0.33 | -0.53 |
| Average Basic Shares Outstanding | 94.93M | 87.96M | 87.01M | 79.41M | 62.84M |
| Average Diluted Shares Outstanding | 94.93M | 87.96M | 87.01M | 79.41M | 62.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |